Evolocumab for homozygous familial hypercholesterolaemia, October 2019
Page last updated: 6 March 2020
Drug utilisation sub-committee (DUSC)
October 2019
Abstract
Purpose
To compare the predicted and actual utilisation of evolocumab for homozygous familial hypercholesterolaemia (HoFH) in the first 24 months of PBS listing. Evolocumab was PBS listed for this indication on 1 December 2016.
Date of listing on the Pharmaceutical Benefits Scheme (PBS)
Evolocumab was first PBS listed for the treatment of homozygous familial hypercholesterolaemia on 1 December 2016.
Data Source / methodology
The analyses used data from the PBS supplied prescriptions and authority approvals databases.
Key Findings
- The actual number of patients treated with evolocumab for HoFH in the first two years of listing was higher than expected.
- In 2018, 1,098 patients were supplied at least one prescription for HoFH and, of these, 574 patients were supplied their first PBS‐subsidised evolocumab prescription.
- The total number of prescriptions supplied for evolocumab for HoFH was similar to predicted in year one of listing but was greater than predicted in year two.
- In 2018, the majority of evolocumab prescriptions supplied for HoFH were for the 140 mg/mL pen device (6,996 prescriptions; 96%)
